MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.512
AS - Asia 2.988
EU - Europa 2.698
SA - Sud America 364
AF - Africa 124
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.449
RU - Federazione Russa 1.150
CN - Cina 881
SG - Singapore 804
IT - Italia 617
HK - Hong Kong 360
KR - Corea 288
BR - Brasile 286
VN - Vietnam 237
IE - Irlanda 187
FR - Francia 125
SE - Svezia 109
DE - Germania 103
IN - India 97
PL - Polonia 94
FI - Finlandia 84
NL - Olanda 74
BD - Bangladesh 60
JP - Giappone 56
GB - Regno Unito 50
ID - Indonesia 45
JO - Giordania 41
CA - Canada 34
AU - Australia 32
MA - Marocco 32
AR - Argentina 31
NG - Nigeria 27
ES - Italia 23
MX - Messico 23
TR - Turchia 23
CH - Svizzera 21
EC - Ecuador 19
IQ - Iraq 19
ZA - Sudafrica 19
IR - Iran 17
CI - Costa d'Avorio 13
EG - Egitto 12
UA - Ucraina 12
AT - Austria 9
PH - Filippine 9
UZ - Uzbekistan 9
CO - Colombia 8
MY - Malesia 8
BJ - Benin 7
PK - Pakistan 7
SA - Arabia Saudita 7
KE - Kenya 6
LV - Lettonia 5
PY - Paraguay 5
VE - Venezuela 5
DZ - Algeria 4
LT - Lituania 4
UY - Uruguay 4
CL - Cile 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
CZ - Repubblica Ceca 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.720
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.089
Singapore 623
Ashburn 487
Hong Kong 320
Hefei 309
Seoul 287
San Jose 217
Dublin 187
Beijing 132
Chandler 112
Milan 103
Fairfield 99
Ho Chi Minh City 91
Florence 86
Warsaw 83
Kent 82
Los Angeles 77
Council Bluffs 70
Lauterbourg 64
Buffalo 57
Hanoi 54
Tokyo 54
Munich 51
Moscow 50
Altamura 45
Lawrence 45
The Dalles 44
Rome 42
Dallas 39
Mumbai 39
Boston 37
Seattle 37
Paris 34
São Paulo 34
Wilmington 33
Cambridge 32
Jakarta 32
Lappeenranta 32
Woodbridge 32
Princeton 31
New York 29
Houston 28
Turku 28
Melbourne 27
Abuja 26
Casablanca 25
Helsinki 24
Shanghai 24
Frankfurt am Main 22
Chicago 19
Bengaluru 18
Clifton 18
Orem 15
Da Nang 14
Abidjan 13
Chennai 13
Johannesburg 13
Rio de Janeiro 13
West Jordan 13
Hamburg 12
Bern 11
Guangzhou 11
London 11
Naples 11
Barcelona 10
Dearborn 10
Istanbul 10
Modena 10
Turin 10
Bologna 9
Medford 9
Quito 9
Stockholm 9
Toronto 9
Trieste 9
Amsterdam 8
Belo Horizonte 8
Brooklyn 8
Cairo 8
Gdansk 8
Pune 8
San Diego 8
Ann Arbor 7
Atlanta 7
Catania 7
Cotonou 7
Denver 7
Manchester 7
Norwalk 7
Ottawa 7
Porto Alegre 7
Tashkent 7
Tehran 7
Burgum 6
Genoa 6
Guayaquil 6
Madrid 6
Nuoro 6
Romola 6
Amman 5
Totale 6.088
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 407
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 211
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 207
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 203
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 200
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 198
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 195
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 189
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 186
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 184
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 178
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 175
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 170
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 170
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 170
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 168
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 166
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 164
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 163
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 162
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 158
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 155
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 153
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 152
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 152
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 151
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 146
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 144
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 144
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 144
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 141
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 140
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 137
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 137
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 136
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 133
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 132
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 129
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 129
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 128
Antibody-mediated cell depletion therapies in multiple sclerosis 126
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 123
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 122
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 121
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 120
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 118
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review 117
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis 113
Magnetic Resonance intracranial Vessel Wall Imaging (VWI) in Susac Syndrome: potential relevance for diagnosis and therapeutic management. 112
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 112
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 112
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) 109
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 109
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 106
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 106
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 106
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 104
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 103
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 102
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 100
Preface 100
Low positive predictive value of Multiple Sclerosis diagnostic criteria in demyelinating syndromes with red flags of better explanation. 97
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 89
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 86
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study 85
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 84
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT 83
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation 76
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 72
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 59
Cell phenotype classification by NMR spectroscopy of intact cell lines 28
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party 22
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK 20
Should autologous HSCT be a first-line option in highly active MS: YES 8
Totale 9.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.546
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.546
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 0 6 8
2021/2022205 2 15 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/20253.545 126 327 201 503 828 561 109 230 145 96 167 252
2025/20264.395 547 666 609 523 429 144 517 192 261 309 198 0
Totale 9.857